4 results
Part 1: To assess the safety, tolerability and pharmacokinetic-dynamic response, of single escalating doses of EA-230 in healthy subjects.Part 2: To assess the dose-and plasma concentration-response relation of single escalating doses EA-230 on…
1.) First, we hypothesize that a reduction of myocardial damage explained by lower levels of myocardial damage markers (e.g. troponin I, CK-MB) by sevoflurane may be related to a reduction of inflammatory mediators (i.e. TNF-α, CD11b/CD18 cells, and…
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB074 in subjects with neuropathic PLSR.
To assess safety and tolerability of EA-230 in patients undergoing cardiac surgery with cardiopulmonary bypass.To assess the anti-inflammatory effects of EA-230 in patients with systemic inflammation following cardiac surgery. To assess the effects…